

March 12, 2020

**BSE Limited**  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.

**National Stock Exchange of India Limited**  
Listing Department  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

Scrip code: **512529**

Symbol: **SEQUENT**

**Subject: Press Release – Sequent Scientific announces WHO-Geneva approval for its Vizag facility**

Dear Sir / Madam,

We enclose herewith a copy of Press Release that is being issued by the Company, in connection with the above-mentioned subject.

You are requested to take the same on record.

Thanking you.

Yours faithfully  
For **Sequent Scientific Limited**

**Krunal Shah**  
Company Secretary & Compliance Officer



Encl.: as above

**SeQuent Scientific Limited**

## Sequent Scientific announces WHO-Geneva approval for its Vizag facility

**Mumbai, March 11, 2020:** SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services, today announced receipt of WHO – GENEVA approval for API Praziquantel (Anthelmintic) under pre-qualification program

Alivira's Vizag site is India's only US FDA-authorized and EU GMP-compliant facility focused on production of active pharmaceutical ingredients (APIs) for the animal health sector.

The Vizag site is a multipurpose manufacturing facility equipped with reactor capacity of 225KL and six clean rooms. The site began commercial production in 2015 and has been successfully inspected by USFDA during 2016 and 2018.

This approval further emphasizes our focus on compliance standards.

### About SeQuent Scientific Limited

---

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

### For details, feel free to contact:

---

**Tushar Mistry**

Chief Financial Officer  
Tel: +91 22 4111 4717  
[tushar.m@sequent.in](mailto:tushar.m@sequent.in)

**Diwakar Pingle**

Christensen Investor Relations  
Tel : +91 22 4215 0210  
[sbubna@christensenir.com](mailto:sbubna@christensenir.com)

**Abhishek Singhal**

Investor Relations Consultants  
[abhishek.s@sequent.in](mailto:abhishek.s@sequent.in)

**Registered Office**

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: [www.sequent.in](http://www.sequent.in)

*Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*